Tirzepatide

Tirzepatide is a dual GIP/GLP-1 receptor agonist that is FDA-approved as the prescription drugs Mounjaro and Zepbound. Research-chemical versions sold for laboratory use are not the approved product and are not for human use. This page is purely educational and is not medical advice; any decision about tirzepatide belongs with a licensed clinician.

Important: The molecule tirzepatide IS an approved medicine, dispensed as a finished injection product. It is also sold separately as a "research only" lyophilized powder, which is not the approved drug and is not quality-controlled as a medicine. WikiPeps does not sell tirzepatide, does not provide sourcing guidance, and does not publish human dosing protocols.

What is Tirzepatide?#

Tirzepatide is a single engineered peptide that activates two different gut-hormone receptors at the same time: the GIP (glucose-dependent insulinotropic polypeptide) receptor and the GLP-1 (glucagon-like peptide-1) receptor. Because it works on both, it is described as a dual incretin receptor agonist. It is the active ingredient in the FDA-approved products Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea in adults with obesity). It was previously known in development as LY3298176.

How does Tirzepatide work?#

Tirzepatide engages two incretin pathways that the body normally uses to manage blood sugar and appetite after eating:

• GLP-1 receptor activation stimulates insulin release when blood sugar is high, reduces glucagon (a hormone that raises blood sugar), slows gastric emptying, and increases satiety.
• GIP receptor activation is thought to add complementary effects on insulin response and energy balance.

The two are not engaged equally. Published pharmacology describes tirzepatide as an "imbalanced" and biased agonist: it binds the GIP receptor with affinity comparable to the native hormone, while its affinity for the GLP-1 receptor is markedly weaker than native GLP-1. Its long elimination half-life of roughly 5 days in humans is what allows the approved drug to be given once weekly.

What is Tirzepatide studied for?#

In humans, tirzepatide has been studied in large randomized phase 3 programs (the SURPASS trials in type 2 diabetes and the SURMOUNT trials in obesity), which supported its FDA approvals. This is a contrast to many research peptides, where human evidence is thin.

The strong human evidence above applies to the FDA-approved finished products, not to unverified research-chemical powders.

Is Tirzepatide legal and FDA-approved?#

Yes — the molecule is FDA-approved. Mounjaro was approved in 2022 for blood-sugar control in adults with type 2 diabetes, and Zepbound was approved in 2023 for chronic weight management, with a later indication for moderate-to-severe obstructive sleep apnea in adults with obesity. These are prescription medicines that should be obtained through a licensed pharmacy with a valid prescription.

However, "research use only / not for human consumption" tirzepatide is not the approved product. It is not manufactured or tested to pharmaceutical standards, and using it in or on a person is not legal or safe. The FDA has stated the tirzepatide shortage is resolved and ended enforcement discretion for mass compounding of tirzepatide (for 503A pharmacies in February 2025 and 503B outsourcing facilities in March 2025), which a federal court upheld. WikiPeps does not provide sourcing guidance for any version.

How is Tirzepatide dosed in research?#

There is no validated human dose published on WikiPeps, and WikiPeps does not publish dosing protocols. The approved drugs Mounjaro and Zepbound have specific, clinician-directed titration schedules in their prescribing information, but those are clinical decisions made and supervised by a licensed prescriber — they are not self-administration instructions and are intentionally not reproduced here. For research-chemical material, there is no legitimate human dose at all. Any dosing question should go to a licensed clinician.

How is Tirzepatide reconstituted?#

The FDA-approved products do not require patient reconstitution — they are supplied as finished, ready-to-use injection products. The lyophilized "research only" powder is a different, non-medicinal item. For the general principles of safely handling and reconstituting a lyophilized peptide in a laboratory context, see our educational guide: How to reconstitute a peptide. That guide is for understanding the process only and is not instruction to prepare anything for human use.

What are the safety considerations?#

For the approved drug, commonly reported side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — particularly when starting or increasing the dose. The prescribing information carries a boxed warning about thyroid C-cell tumors observed in rodents; tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other described risks include pancreatitis, gallbladder problems, hypoglycemia when combined with certain other diabetes medicines, and dehydration-related kidney injury from severe GI symptoms.

These risks are characterized for the regulated, quality-controlled product. With unverified research-chemical powders, purity, identity, and sterility are unknown, which adds further hazard on top of the drug's own risk profile. Only a licensed clinician can weigh any of this for an individual.

The bottom line#

Tirzepatide is a dual GIP/GLP-1 receptor agonist with strong human evidence and real FDA approvals as Mounjaro and Zepbound. That makes it different from most research peptides — but it is still a serious medicine with a boxed warning and meaningful risks. The approved products come ready to use from a pharmacy; "research only" powders are not the approved drug and are not for human use. Use this page to understand the molecule, and take every dosing or treatment decision to a licensed clinician.